Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression
Bladder Cancer · 2026-06 · 12 (2)
DOI: 10.1177/23523735261447112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 05.05.2026. Verfasst von Jessica L Neil und 13 weiteren Autor:innen. Beteiligte Einrichtung: Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, School of Medicine and Health, University of Birmingham, Birmingham, UK. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity. The GALEAS Bladder (GB) gene panel covers several actionable mutations, including in FGFR3.
Objective
To modify GB to detect FGFR3 fusions as well as single nucleotide variants and assess its potential as a urine-based companion diagnostic. We also study tissue-urine concordance and associations between FGFR3 genomic alterations and FGFR3 expression.
Methods
Probes were added to GB covering the 3’-region of FGFR3. The new panel was used to analyse genomic DNA extracted from 158 frozen primary BCs. Mutation concordance was also analysed in 107 tumour-urine pairs. Associations between FGFR3 mutations and expression were analysed in 608 FFPE BCs with the Decipher Bladder transcriptome assay. Results and limitations FGFR3-TACC3 fusions were found in 3/3 positive controls and 4/158 frozen BCs. Fusions were also detectable in genomic DNA from FFPE tumour and urine cell pellet DNA. All fusions were corroborated by PCR and Sanger sequencing. FGFR3 mutation status in urine was 94.4% concordant (95% CI 87.7–97.7%); GB detected mutations in urine with 92.1% sensitivity (95% CI 81.7–97.0%) at 97.7% specificity (95% CI 86.5–99.9). All FGFR3 mutations were associated with increased FGFR3 expression. This is a proof-of-principle study, rather than definitive evidence of utility as a companion diagnostic, with the need for fusion detection validation in larger patient cohorts.
Conclusions
In addition to BC detection, a modified version of GB demonstrates feasibility for tissue and urine-based detection of FGFR3 fusions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, School of Medicine and Health, University of Birmingham, Birmingham, UK.
- Erasmus University Medical Centre, Rotterdam, the Netherlands.
- Veracyte Inc., South San Francisco, CA, USA.
- Department of Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
- Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
- Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.
Zitieren
APA
Neil, J. L., Gordon, N. S., Goel, A., Myumyun, A. N., Tura, B., de Jong, J. J., Davicioni, E., Zeegers, M. P., Cheng, K. K., James, N. D., Neou, M., Arnold, R., Bryan, R. T., & Ward, D. G. (2026). Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression. Bladder Cancer, 12(2). https://doi.org/10.1177/23523735261447112
Vancouver
Neil JL, Gordon NS, Goel A, Myumyun AN, Tura B, de Jong JJ, et al. Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression. Bladder Cancer. 2026;12(2). doi:10.1177/23523735261447112
BibTeX
@article{Neil2026,
author = {Neil, Jessica L and Gordon, Naheema S and Goel, Anshita and Myumyun, Ayse N and Tura, Benjamin and de Jong, Joep J and Davicioni, Elai and Zeegers, Maurice P and Cheng, Kar Keung and James, Nicholas D and Neou, Mario and Arnold, Roland and Bryan, Richard T and Ward, Douglas G},
title = {Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression},
journal = {Bladder Cancer},
year = {2026},
volume = {12},
number = {2},
doi = {10.1177/23523735261447112}
}
EUVIMED